Related Experiment Videos
Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse
K D Bardhan1, S Singh, P Morris
1Rotherham General Hospital NHS Trust, South Yorkshire, UK.
Italian Journal of Gastroenterology and Hepatology
|April 1, 1997
Summary
Daily low-dose colloidal bismuth subcitrate effectively reduces duodenal ulcer relapse. This treatment for peptic ulcers was well-tolerated and showed significant long-term benefits.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Duodenal ulcers represent a significant gastrointestinal condition.
- Preventing ulcer relapse is crucial for patient well-being and reducing healthcare burden.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose colloidal bismuth subcitrate (CBS) in preventing duodenal ulcer recurrence.
- To compare CBS with ranitidine and placebo in a maintenance phase study.
Main Methods:
- A double-blind, randomized clinical trial involving 194 patients with active duodenal ulcers.
- A 12-week healing phase followed by a 12-month maintenance phase with different treatment arms.
- Assessment included clinical evaluation, endoscopy, and blood bismuth levels.
Main Results:
- Cumulative healing rates at 12 weeks were high for both colloidal bismuth subcitrate (93%) and ranitidine (97%).
- One-year relapse rates were significantly lower with active treatments: ranitidine (21%), colloidal bismuth subcitrate (33%), versus placebo (60%).
- Treatment was well-tolerated, with low blood bismuth levels during maintenance therapy.
Conclusions:
- Nightly low-dose colloidal bismuth subcitrate (120 mg) is an effective strategy for reducing duodenal ulcer relapse.
- The treatment demonstrates a favorable safety profile and tolerability.
- Colloidal bismuth subcitrate offers a valuable therapeutic option for long-term duodenal ulcer management.